Evaluate the Efficacy and Safety of Aspirin in Combination With Trametinib and Dabrafenib

Sponsor
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Study ID
NCT05988697
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Advanced Cancer
  • BRAF V600E Mutation
  • NSCLC
  • Stage IIIB NSCLC
  • Stage IV NSCLC

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

The purpose of this study is to observe the safety and efficacy of Aspirin combined with Trametinib and Dalafenib in the treatment of advanced BRAF V600E mutated non-small cell lung cancer (NSCLC)

Key Dates

Start date
Nov 1, 2023
Status verified
Oct 2023
Primary completion
Sep 1, 2026
Completion
Apr 1, 2027

Study Design

Enrollment
36 participants (estimated)

Arms

  • Arm: Observation group
    Primary IIIB-IV BRAF V600E mutated advanced non-small cell lung cancer in a population of patients with advanced lung cancer proposed to be treated with Trametinib， Dabrafenib and Asprin

Primary Outcome Measure

PFS [ Time Frame: 3 years ]

Central Contacts

Related Studies